Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Fineline Cube Sep 7, 2026
Company PIC

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Fineline Cube Sep 7, 2026
Company Drug PIC

Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression

Fineline Cube Sep 7, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Drug

NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer

Fineline Cube Sep 7, 2026
Company Deals

Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206

Fineline Cube Mar 5, 2025

China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting...

Company Deals

Hainan Poly Pharm’s US Partner Slate Run Pharmaceuticals Collaborates with Premier on Contrast Agents

Fineline Cube Mar 5, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced a significant partnership between its US...

Company Deals

Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies

Fineline Cube Mar 5, 2025

US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement...

Company

MSD China Reorganizes to Boost Mature Product Lines

Fineline Cube Mar 5, 2025

Anna Van Acker, Senior Vice-President of Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and...

Company Drug

Suzhou Abogen’s RSV mRNA Vaccine IND Approved by China’s CDE

Fineline Cube Mar 5, 2025

China-based nucleic acid drug developer Suzhou Abogen Biosciences announced that the Investigational New Drug (IND)...

Policy / Regulatory

CDE Launches SPARK Project to Boost Pediatric Antitumor Drug R&D

Fineline Cube Mar 5, 2025

China’s Center for Drug Evaluation (CDE) has released a notification to solicit feedback on its...

Company Drug

BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment

Fineline Cube Mar 5, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...

Company

Organon’s 2024 Financial Report Shows Steady Growth in Women’s Health and Biosimilars

Fineline Cube Mar 4, 2025

Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study

Fineline Cube Mar 4, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the...

Company

Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents

Fineline Cube Mar 4, 2025

The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...

Company Drug

Genentech’s TNKase Approved by FDA for Acute Ischemic Stroke Treatment

Fineline Cube Mar 4, 2025

Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic...

Company Drug

Eisai’s Lecanemab Rejected by Australia’s TGA for Early Alzheimer’s Treatment

Fineline Cube Mar 4, 2025

Japan-based Eisai Co., Ltd (TYO: 4523) announced that the Therapeutic Goods Administration (TGA) of Australia...

Company Deals Medical Device

Boston Scientific to Acquire SoniVie, Boosting Hypertension Treatment Portfolio

Fineline Cube Mar 4, 2025

Boston Scientific Corporation (NYSE: BSX) is set to acquire SoniVie Ltd, an Israel-based medical device...

Company Drug

Fapon Biopharma’s FP008 Receives FDA Approval for Clinical Trials

Fineline Cube Mar 4, 2025

China-based Fapon Biopharma announced that it has received clinical trial approval from the US Food...

Company Deals

Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development

Fineline Cube Mar 4, 2025

Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...

Company Drug

GSK’s Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic

Fineline Cube Mar 4, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA)...

Company Drug

Juvestar and Raziel Therapeutics Launch Phase III Study for RZL-012 in China

Fineline Cube Mar 4, 2025

Juvestar Biotech Co., Ltd., a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...

Company Medical Device

Waters and Kehua’s LC-MS Systems Gain NMPA Approval for IVD Use

Fineline Cube Mar 4, 2025

Two home-grown liquid chromatography with tandem mass spectrometry (LC-MS) systems, the ACQUITY UPLC I-Class PLUS...

Company Drug

Zai Lab’s Augtyro Receives TFDA Approval for ROS1-Positive NSCLC and NTRK Fusion Solid Tumors

Fineline Cube Mar 4, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received marketing...

Company Deals

Shanghai BioScience Completes RMB 100M Financing Round Led by HUAGAI Capital

Fineline Cube Mar 4, 2025

China-based Shanghai BioScience Co., Ltd., a life sciences service platform, announced the completion of a...

Posts pagination

1 … 253 254 255 … 717

Recent updates

  • HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
  • NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer
  • Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery
  • Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt
  • Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Company Drug

NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer

Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Company PIC

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.